Cdc20: A potential novel therapeutic target for cancer treatment

Zhiwei Wang, Lixin Wan, Jiateng Zhong, Hiroyuki Inuzuka, Pengda Liu, Fazlul H. Sarkar, Wenyi Wei

Research output: Contribution to journalReview articlepeer-review

50 Citations (Scopus)

Abstract

The Anaphase Promoting Complex (APC) has been characterized to play pivotal roles in regulating the timely cell cycle progression by forming two functionally distinct E3 ubiquitin ligase sub-complexes, APCCdc20 and APCCdh1. Interestingly, recent studies have shown that Cdh1 is functioning as a tumor suppressor whereas Cdc20 may function as an oncoprotein to promote the development and progression of human cancers. In this review, we will discuss the physiological role of Cdc20 and its downstream substrates in vitro and in the transgenic mouse model reminiscent of the pathogenesis of human cancers. Furthermore, we summarize recent findings to indicate that Cdc20 may represent a promising therapeutic target, thus development of Cdc20 inhibitors could be useful for achieving better treatment outcome of cancer patients.

Original languageEnglish
Pages (from-to)3210-3214
Number of pages5
JournalCurrent Pharmaceutical Design
Volume19
Issue number18
DOIs
Publication statusPublished - 2013
Externally publishedYes

Keywords

  • Cancer
  • Cdc20
  • Cell growth
  • Oncogene
  • Therapy
  • Ubiquitination

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Cdc20: A potential novel therapeutic target for cancer treatment'. Together they form a unique fingerprint.

Cite this